Canadian National Vaccine Safety Network (CANVAS)
The Canadian Vaccine Safety Network (CANVAS) assesses vaccine safety immediately after implementation of vaccine campaigns. The network is comprised of sites in Vancouver, Calgary, Toronto, Ottawa, Quebec City, Sherbrooke, and Halifax.
CANVAS initiated its eight annual influenza vaccine safety surveillance campaign, with more than 35,000 participants providing safety data in this year’s cohort. CANVAS submitted weekly safety reports to the Public Health Agency of Canada in October, November and December. Safety information on the following 7 influenza vaccines was captured: Flumist, Fluviral, Vaxigrip, Agriflu, Fluzone, Influvac and Fluad. No unexpected side effects were observed in adults or children following the 2016 seasonal vaccines, although a slighter higher rate of events was reported among 2016 vaccinees.
In 2014 and 2015, CANVAS rapidly implemented safety surveillance for a new meningococcal B vaccine used during a mass immunization campaign following an outbreak of meningococcal B disease in the Saguenay Lac St Jean regions of Quebec and Wolfville, Nova Scotia. In addition to the successful influenza vaccine safety surveillance campaign, CANVAS will also continue to monitor vaccine safety for other and new vaccines, and provide a platform for vaccine acceptability studies.
- Brenda Coleman, Mount Sinai Hospital
- Gaston De Serres, Université Laval
- Jennifer Isenor, Dalhousie University
- Jim Kellner, University of Calgary
- Anne McCarthy, Ottawa Hospital Research Institute
- Shelly McNeil, Dalhousie University
- Karina Top, Dalhousie University
- Louis Valiquette, Université Sherbrooke
- Otto Vanderkooi, University of Calgary